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Case Presentation

A 54 year-old male presented to the hospital with a two week
history of new onset jaundice, anorexia and fatigue. The
patient has a past medical history of hypertension, coronary
artery disease, and ischemic cardiomyopathy with an ejection
fraction of 10% to 15%. He also has a history of atrial fibrillation
and paroxysmal ventricular tachycardia with an automated
implantable cardioverter-defibrillator placed. He denied
any history of blood transfusions, alcohol use, intravenous
drug abuse, or known hepatitis. He also denied taking herbal
medications or vitamins. The patient denied fevers, night sweats,
nausea, shortness of breath, abdominal pain, blood in his stool,
or easy bruising. Four weeks prior to admission, the patient
was diagnosed with hyperthyroidism thought to be secondary to
long-term amiodarone use which the patient had been taking for
eight years for treatment of atrial fibrillation. At that time he was
started on 10 mg of methimazole daily, and his amiodarone was
stopped. All of his other medications were chronic and include
atenolol, pantoprazole, aspirin, clopidogrel, and furosemide. He
has no known drug allergies. Upon admission his methimazole
was stopped since his symptoms could be attributable to this
medication.
On presentation the patient was afebrile. His pulse was regular
at 112 beats/minute, and his blood pressure was 91/61 mm
Hg. He was orientated to person, place, and time. His exam
was noteworthy for scleral icterus and jaundice. There was no
ascites, asterixis, palmer erythema, spider angiomata or other
evidence of liver disease. His abdominal exam was benign, with
no tenderness to palpation, organomegaly, or lymphadenopathy.

Laboratory results are shown in Table 1. All other laboratory
values were within the reference range. An EKG did not show
any acute changes, and three consecutive troponins were
negative. An abdominal ultrasound was notable for the presence
of hepatosplenomegaly with the liver measuring 14.4 cm in
sagittal length and the spleen measuring 14.4 cm. Color doppler
ultrasound showed patent portal, hepatic, and splenic veins.
There was no biliary ductal dilation, cholelithiasis or sludge.
On hospital day two the patient’s clinical status had not
improved, and a liver biopsy was obtained to help differentiate
the cause of hepatic dysfunction. The liver biopsy (Figure 1)
showed severe cholestasis with mild inflammatory changes
and mallory bodies on pathology. Given the time course of
introduction to methimazole and the development of abnormal
liver tests, the presumptive diagnosis of methimazole-induced
hepatotoxicity was made. The patient experienced a relatively
stable course until day six of his stay. At that time the patient
became clinically unstable, went into cardiac arrest and died. It
was presumed that the new onset liver failure proved to be too
much of a stressor on an already weak heart.

Discussion

Methimazole and its precursor molecule carbimazole are
common treatment options for hyperthyroidism but do not
come without significant risk to the patient: methimazole is
a known hepatotoxin. An extensive review of the literature
has not identified any previous case reports of methimazoleinduced liver injury leading to death in the United States. There
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Sodium 140
mmol/l

Potassium
4.1 mmol/l

Chloride
105 mmol/l

Carbon Dioxide
21 mmol/l

CBC

White Blood
Cell
10.2 b/l

Hemoglobin
14.7 g/dl

Hematocrit
46.0 %

Platelets 137 b/l

LFTs

Protein
5.1 g/dl

Albumin
2.8 g/dl

Total Bilirubin
26.8 mg/dl

Coags

Protime
22.8 s

Prothrombin
Time 33 s

INR 1.90

Serologies

HAV IgM (-)

HAV IgG (+)

HBV Ant (-)

TFTS

Thyroid
Stimulating
Hormone
0.02

Thyroxine
4 1.5

Triiodothyronine
3 63

Table 1. Laboratory values at presentation.
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He did have 2+ lower extremity swelling that was thought to be
chronic and secondary to his heart disease.

Urea-Nitrogen 58
mg/dl

Creatinine
2.2 mg/dl

Glucose
136 mg/dl

Direct Bilirubin
11.4 mg/dl

Aspartate
Aminotransferase
107 IU/l

Alanine
Aminotransferase
107 IU/l

Alkaline
Phosphatase
82 IU/l

HBV Core (-)

HBV Ab (-)

HCV Ab (-)

Case Reports

was a case report of necrotizing hepatitis leading to death in
Germany.1 There have been case reports associating fulminant
hepatic failure and death with the antithyroid agent propylthiouracil in the United States. 2,3 However, up to this point
methimazole liver injury has not been associated with any
deaths in the United States.
There were many diagnoses in the differential that were
sequentially ruled out during this patient’s admission, including
chronic viral hepatitis, biliary and portal vein thrombosis,
infiltrative and chronic passive congestion, and ischemic liver
injury. One drug considered in addition to methimazole for
causing hepatotoxicity in this patient was amiodarone. It was
difficult to apply the established scoring systems for assessing
causality between a drug and hepatocellular injury in this case
because the patient expired before rechallenge of the potential
offending agent was possible. However, considering the
temporality of the treatment, it is likely that methimazole and
not amiodarone was the cause of liver injury. The patient had
been stable on amiodarone for eight years without any noted
hepatotoxicity. In contrast, methimazole had been started four
weeks prior to development of jaundice. The aforementioned
scoring systems for deducing the cause of drug-induced liver
injury put a much greater weight on drugs that cause injury in
a window of roughly five days to three months. The patient’s
amiodarone use did not fall into this time interval. In fact, the
median time for liver disease associated with amiodarone is 21
months after initiation.19
The liver biopsy was also not consistent with amiodarone-induced
liver injury. Changes in pathology that are usually associated with
amiodarone drug toxicity include Mallory’s hyaline, steatosis,
ballooning of hepatocytes, focal necrosis, fibrosis, and in severe
cases, cirrhosis.6 Although our patient did have Mallory bodies
on specimen, none of the other defining characteristics of
amiodarone toxicity were present. As mentioned, the biopsy
showed diffuse cholestasis with intracanalicular bile plugging
(Figure 1). As of 1999 there had only been seven case reports
published of jaundice and cholestatisis presenting as the major
clinical and pathological manifestations of amiodarone induced
hepatotoxicity.7 Conversely, the majority of methimazole liver
injury cases have reported cholestasis and associated jaundice.8-14
This case serves as an example of a serious but uncommon drug
related liver injury. Generally, patients with severe liver injury,
as defined by serum ALT being three times the upper limit of
normal or the serum bilirubin being two times the upper limit
of normal in the absence of biliary obstruction, have a mortality
of at least 10%.15 In our case the patient had a bilirubin that
was over 20 times normal levels. Additionally, our patient
had two of the three hallmarks of acute liver failure: jaundice
and impaired hepatic synthetic function. During the course
of his admission he did not develop the third characteristic
which is encephalopathy. If the full triad of manifestations is

present in cases of drug induced hepatotoxicity, patients have
roughly a 25% survival rate without liver transplant.16 However,
prognosis also depends on agent as there is a 0% mortality of
erythromycin induced liver failure versus 40% mortality with
use of halothane.19
It is of crucial importance to recognize drug induced liver toxicity
because it is now the leading cause of acute liver failure among
patients referred for liver transplantation in the United States.17
Hepatotoxicity related specifically to antithyroid agents occurs
with an approximate frequency of 0.1% to 0.2%.18 It is plausible,
however, that this number may be falsely low secondary to
difficulty in diagnosis and underreporting.
In this case, the patient’s co-morbidities allowed for close
physician follow up and an apparent drug induced liver injury
was caught just four weeks after the inciting agent was started.
However, not all patients will be followed so vigilantly after
starting potentially hepatotoxic drugs. It is important for the
responsible physician to be aware of potential liver injury that
drugs such as methimazole may cause in order to prevent their
rare but unfortunate complications.

Figure 1. Liver biopsy shows diffuse cholestasis, mallory bodies,
and intracanalicular bile plugging. There were no viral inclusion
bodies, steatosis, necrosis, or fibrosis.
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